Skip to main content
Caplight Logo









GlyTherix Ltd

GlyTherix Ltd

Private
SydneyHealthcare & Life Scienceshttps://glytherix.com/

Last Round

Series B

Feb 16, 2024

Total Funding Raised

$2.14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GlyTherix Ltd is a biotechnology company that develops a targeted radiotherapy platform designed to treat solid tumors by delivering antibody radiopharmaceuticals.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Imaging, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

theranosticstargeted radiotherapyradioligand therapyantibody therapeuticsradiopharmaceuticalsGPC-1 targetsolid tumor therapyMiltuximabsee and treatlutetium-177zirconium-89cancer imagingPET imagingprostate cancer treatmentpancreatic cancer treatmentclinical-stage biotechantibody drug conjugatesADC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GlyTherix Ltd Comparables

Compare GlyTherix Ltd with similar companies based on industry and business-model similarity.

GlyTherix Ltd comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Precirix
82%
Alpha-9 Oncology
79%
Radiopharm Theranostics
77%

GlyTherix Ltd Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 16, 2024
Series AJul 22, 2023
GrantSep 8, 2022
GrantDec 1, 2021
GrantMar 3, 2021
Grant
Jul 16, 2020

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 87% MoM, reaching 2.4K.

  • Jan 8, 2026

    Monthly visitors increased 118% MoM, reaching 2K.

GlyTherix Ltd Filings

Explore SEC and related filing metadata, where available.

GlyTherix Ltd filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GlyTherix Ltd's valuation, stock price, and market status.

Is GlyTherix Ltd a public or private company?

GlyTherix Ltd is a private company.

What is the current stock price of GlyTherix Ltd?

GlyTherix Ltd is a private company with no public stock price. No recent secondary market data is available.

How much is GlyTherix Ltd worth (valuation)?

Valuation information for GlyTherix Ltd is not publicly available.

Can I buy GlyTherix Ltd stock?

GlyTherix Ltd shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GlyTherix Ltd's last funding round?

GlyTherix Ltd's most recent funding round was Series B on February 16, 2024.

Who are the main investors in GlyTherix Ltd?

Key investors in GlyTherix Ltd include Australian Research Council, Therapeutic Innovation Australia, NSW Government, Australian Federal Government (Cooperative Research Centres Projects grant).

Will GlyTherix Ltd IPO soon?

No public IPO plans have been announced for GlyTherix Ltd.

How can I track GlyTherix Ltd secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GlyTherix Ltd's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range5
Year Founded2017
Last FundingFeb 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?